News|Articles|March 27, 2020

In the Lab eNewsletter

  • Pharmaceutical Technology's In the Lab eNewsletter-04-01-2020
  • Volume 15
  • Issue 4

Integra Now Offers New High-Volume Pipettes

The company has launched new high volume eight- and 12-channel pipettes, offering a capacity of 1250 µL per channel.

Integra Biosciences has expanded its comprehensive collection of pipettes with the launch of two new EVOLVE manual pipettes. The company now offers high-volume eight- and 12-channel options, offering a capacity of 1250 µL per channel, the company announced in a March 3, 2020 press release.

The EVOLVE pipette family now comprises an assortment of single-, eight-, 12-, and 16-channel manual pipettes, covering a volume range of 0.2 µL to 5000 µL, making them suitable for cell culture applications. The manually actuated plunger can generate significantly more force for aspirating and dispensing than an electronic pipette, which offers the advantage of vigorous mixing and breaking up of cell pellets. The new pipettes retain all the same beneficial features of the EVOLVE product line, including quick-set dials for volume setting and a lightweight ergonomic design for more comfortable and productive pipetting.

The new pipettes also use the company’s GripTip pipette tips, which include a range of specialty tips aimed at cellular applications, such as 1250 µL short tips-for more ergonomic pipetting-and wide bore tips, which help to eliminate cell shearing and aid pipetting of viscous solutions.

For higher throughput cell-based applications, the company also offers the VIAFLO 96/384-a compact and easy-to-use solution for 24-, 96-, and 384-channel pipetting-which enables filling, mixing, or seeding of an entire plate in one dispense.

Source: Integra


Related to this article

Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
AAPS PharmSci 360: CMC Strategies, Part 3
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.